Key result
Impella use at transplant centers is linked to ~35% lower mortality and fewer readmissions.
Why the study?
It remained unclear whether the spectrum of MCS devices available and treating hospital type influence clinical outcomes in STEMI complicated by cardiogenic shock.
Does the level of hospital mechanical circulatory support capability affect outcomes in patients with STEMI and cardiogenic shock?
Cohort (n=19,260)
Yes
Does the level of hospital mechanical circulatory support capability affect outcomes in patients with STEMI and cardiogenic shock?
Odds Ratio: 0.65 (95% CI 0.43–0.99)
p-value: p=0.045
In patients with STEMI and cardiogenic shock, treatment at centers with advanced MCS capabilities (such as transplant centers) is associated with lower mortality and readmission rates even when receiving the same device.
No takes yet. Share an insight, caveat, or question.
STEMI-CS patients show similar hospital mortality at MCS vs non-MCS centers; leaves open whether device access improves outcomes in observational data.
Murthi et al. (2026) conducted a cohort in STEMI complicated by cardiogenic shock (n=19,260). Treatment at transplant centers vs. Treatment at centers offering only Impella support was evaluated on In-hospital mortality and 30-day readmission (aOR 0.65, 95% CI 0.43-0.99, p=0.045). Patients receiving Impella at transplant centers had lower mortality (aOR 0.65; 95% CI 0.43-0.99; p=0.045) and lower 30-day readmissions than those treated at centers offering only Impella.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: